Saul H Rosenberg

Saul H Rosenberg

AbbVie Inc - Chicago / United States
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4375688
-
person_outline Saul H Rosenberg's MOST POPULAR ARTICLES
1-) An inhibitor of Bcl-2 family proteins induces regression of solid tumoursT Oltersdorf, SW Elmore, AR Shoemaker, RC Armstrong, DJ Augeri, ...Nature 435 (7042), 677, 200537992005
2-) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAJ Souers, JD Leverson, ER Boghaert, SL Ackler, ND Catron, J Chen, ...Nature medicine 19 (2), 202, 201326162013
3-) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitorC Tse, AR Shoemaker, J Adickes, MG Anderson, J Chen, S Jin, ...Cancer research 68 (9), 3421-3428, 200819152008
4-) Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour …WH Wilson, OA O\'Connor, MS Czuczman, AS LaCasce, JF Gerecitano, ...The lancet oncology 11 (12), 1149-1159, 20109282010
5-) ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor modelsCK Donawho, Y Luo, Y Luo, TD Penning, JL Bauch, JJ Bouska, ...Clinical cancer research 13 (9), 2728-2737, 20079192007